Navigation Links
AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
Date:5/7/2008

All amounts are in U.S. dollars

QUEBEC CITY, May 7 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results for the first quarter ended March 31, 2008.

First Quarter 2008 Highlights

- Cetrorelix: first patients treated in second efficacy trial of the

Phase 3 program in benign prostatic hyperplasia (BPH);

- AEZS-108: first patients treated in Phase 2 trial in ovarian and

endometrial cancers;

- Miltefosine (Impavido(R)): rights sold to Paladin Labs Inc. (TSX:PLB)

for approximately $8.9 million.

Subsequent to First Quarter End

- Cetrorelix: recruitment of 600 patients completed for first efficacy

trial of the Phase 3 program in BPH;

- Juergen Ernst, AEterna Zentaris Chairman, appointed Interim President

and CEO, replacing David J. Mazzo. Departure of Ellen McDonald, Senior

Vice President, Business Operations and Chief Business Officer;

- Board member Jose P. Dorais appointed to the Corporate Governance,

Nominating and Human Resources Committee, replacing Mr. Juergen Ernst,

the Company's Chairman of the Board and Interim President and CEO, who

had previously stepped down from the committee in connection with his

appointment as Interim President and CEO.

Juergen Ernst, Chairman, Interim President and CEO at AEterna Zentaris commented, "During the quarter, we continued to move forward with our Phase 3 program in BPH with our lead compound cetrorelix, as we completed patient recruitment for our first efficacy trial in North America and started
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... by group leader Yung-Eun Sung has announced that ... and nitrogen-doped graphenes which can be applied as ... cells. Yung-Eun Sung is both a group leader ... for Basic Science* (IBS) and a professor at ... great significance with regards to the development of ...
(Date:7/24/2014)... Yushan Yan, Distinguished Professor of Engineering at the ... nanomaterials to solve problems in energy engineering, environmental ... focused on zeolites, porous rock with a well-defined, ... size is so precisely decided that zeolites can ... fraction of an angstrom (one-tenth of a nanometer), ...
(Date:7/24/2014)... , July 24, 2014 Research and ... "Global Cell Culture Market 2014-2018" report to their ... Cell culture is the in vitro growth of ... research, cell studies, and biopharmaceutical production. Cell culture is ... Cell culture instruments and cell culture consumables are necessary ...
(Date:7/24/2014)... 2014 Your cell phone may ... lithium-ion battery storage capacity. , New research indicates ... model created at Lawrence Livermore National Laboratory ... how carbon components will perform as electrodes. , ... urgent need for higher-performance batteries. Several key characteristics ...
Breaking Biology Technology:University of Delaware researcher describes new approach for creating organic zeolites 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2Getting More Life out of Lithium-ion Batteries 2
... - Ranked Number 7 out of top 20 Employers ... 9 EMD Serono, Inc., an affiliate,of Merck KGaA, ... Science magazine as a top employer in the biotechnology ... 20 employers,across the life sciences., "We are honored ...
... (Nasdaq: ERES ), a leading provider of ... to the pharmaceutical,biotechnology, medical device, and related industries, ... quarter results for the period ended,September 30, 2008 ... closes.,After the release, the Company will host a ...
... Million RMB Commercial Bank Loan With Interest Payment ... Biotech Ltd. (Amex:,SVA), a vaccine-focused biotech company in ... Promotion Association at the,Zhongguancun Science and Technology Park ... of that program, Sinovac Biotech Co. Ltd.,s,("the Company") ...
Cached Biology Technology:EMD Serono Named as a Top Employer by Science Magazine 2eResearchTechnology, Inc. to Announce 2008 Third Quarter Results on October 30, 2008 2Sinovac's Credit Rating Upgraded to AAZ, Second Highest Rating 2Sinovac's Credit Rating Upgraded to AAZ, Second Highest Rating 3
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... has different effects on different species of fish, ... of Bristol and Exeter which tested fish anti-predator ... a flying seagull predator model when exposed to ... European minnows. , Lead author Dr Irene ... "Noise levels in many aquatic environments have increased ...
(Date:7/24/2014)... own microbial terroir, meaning the microbial populations found on ... product, creating the final flavor according to research published ... Environmental Microbiology . This is the first time investigators ... , Many sake makers inoculate with both bacteria ... the University of California, Davis, but he and his ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4The microbes make the sake brewery 2
... is pleased to announce the winners of its 2009 ... Plenary Session of the ESA Annual Meeting in Indianapolis, ... be presented on Tuesday, December 15, 7:00-8:00 p.m. ... with full biographies and photos available at http://www.entsoc.org/resources/press_releases/2009-awards.htm ...
... recently completed a comparative analysis of marine ecosystems in ... factors support fisheries production, leading to new insights that ... Known as MENU, for Marine Ecosystems of Norway and ... NOAA Fisheries Service,s Northeast Fisheries Science Center and Alaska ...
... The University of North Carolina at Chapel Hill is ... part of an unprecedented large-scale, collaborative effort by the National ... (NHGRI) to systematically characterize the genomic changes that occur in ... a five-year award, expected to bring $13 to $20 million ...
Cached Biology News:Entomological Society of America names 2009 award winners 2Joint US-Norwegian study provides new insights into marine ecosystems and fisheries production 2Joint US-Norwegian study provides new insights into marine ecosystems and fisheries production 3UNC awarded Cancer Genome Atlas grant 2
RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
EDTA, 0.5 M solution, 100 ml. Ethylene diaminetetraacetic acid.Sterile, nuclease-free. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Human VEGF-D Biotinylated MAb (Clone 78923)...
One-step, microplate or cuvet, colorimetric, linear detection range 0.2 mg/dL to 20 mg/dL. Procedure: 20 min....
Biology Products: